Foghorn Therapeutics

FHTXPhase 1

Foghorn Therapeutics is developing a new class of precision medicines based on its deep understanding of the chromatin regulatory system. Its platform enables the discovery of selective inhibitors of chromatin regulatory complexes, such as the BAF complex, to treat cancers and other serious diseases with high unmet need. The company has advanced multiple candidates into clinical development, including FHD-286 and FHD-609, and has established strategic collaborations with major pharmaceutical partners like Loxo Oncology at Lilly and Merck. Foghorn aims to translate its novel biology insights into transformative therapies for patients.

Market Cap

$293.5M

Employees

100-150

Focus

Biotech

FHTX · Stock Price

USD 5.0010.09 (-66.87%)

Historical price data

AI Company Overview

Technology Platform

The Gene Traffic Control® platform is an integrated discovery engine that maps and targets the chromatin regulatory system to develop selective small molecule drugs against protein-protein interactions within key complexes, enabling a new class of precision medicines.

Pipeline Snapshot

4 drugs in pipeline

Drug	Indication	Stage
Decitabine + Venetoclax + FHD-286	Acute Myeloid Leukemia	Phase 1
FHD-286 + Low Dose Cytarabine + Decitabine	Advanced Hematologic Malignancy	Phase 1
FHD-609	Advanced Synovial Sarcoma	Phase 1
FHD-286	Metastatic Uveal Melanoma	Phase 1

Funding History

Total raised: $340M

IPO$120MUndisclosedOct 9, 2020

Series C$120MEcoR1 CapitalJul 15, 2020

Series B$50MGoogle VenturesJun 15, 2018

Series A$50MFlagship PioneeringDec 15, 2016

Opportunities

Foghorn's primary growth opportunity lies in successfully translating its chromatin platform into clinically validated medicines, which would unlock value across its pipeline and enable expansion into new disease areas.

The strategic collaborations with Lilly and Merck provide significant non-dilutive funding and validate the platform's potential, while also creating future royalty and milestone revenue streams.

Demonstrating proof-of-concept in its ongoing oncology trials could position the company as a leader in the emerging field of transcriptional medicine.

Risk Factors

Key risks include the inherent uncertainty of early-stage clinical trials for novel mechanisms, potential for unforeseen toxicities related to modulating essential chromatin regulators, and intense competition in the oncology and epigenetics space.

The company's valuation is highly sensitive to clinical data readouts, and failure to meet endpoints could significantly impact its financial position and stock price.

Competitive Landscape

Foghorn competes in the epigenetic and transcriptional medicine space against companies like Epizyme (Ipsen), Constellation (MorphoSys), and IDEAYA Biosciences. Its key differentiation is its systematic Gene Traffic Control® platform focused on disrupting specific protein-protein interactions within chromatin complexes, a approach distinct from simply inhibiting enzymatic activity. Its ability to generate both inhibitors and degraders from the same target biology is also a competitive advantage.